Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

dc.contributor.author	Bernal del Castillo, María Teresa
dc.contributor.author	Fernandez Moreno, Ainhoa
dc.contributor.author	LaIglesia, Almudena de
dc.contributor.author	(et al.)
dc.date.accessioned	2023-10-25T08:54:51Z
dc.date.available	2023-10-25T08:54:51Z
dc.date.issued	2023
dc.identifier.citation	Cancer Medicine 12(14), p. 14865-15762 (2023); doi:10.1002/cam4.6120
dc.identifier.issn	2045-7634
dc.identifier.uri	https://hdl.handle.net/10651/69930
dc.description.sponsorship	Jazz Pharmaceuticals
dc.format.extent	p. 14865-15762
dc.language.iso	eng
dc.relation.ispartof	Cancer Medicine
dc.rights	© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
dc.rights	CC Reconocimiento 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	WOS:000993402700001
dc.title	Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
dc.type	journal article
dc.identifier.doi	10.1002/cam4.6120
dc.relation.publisherversion	http://dx.doi.org/10.1002/cam4.6120
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Este ítem está sujeto a una licencia Creative Commons